US-12616724-B2 - Pharmaceutical composition for preventing or treating intestinal damage comprising Leuconostoc citreum strain as active ingredient

Abstract

The present invention relates to a composition comprising a Leuconostoc citreum strain or a culture thereof as an active ingredient for preventing, improving or treating intestinal damage, specifically intestinal damage caused by inflammatory bowel disease, non-alcoholic steatohepatitis or chemotherapy. According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various intestinal damages such as inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy, the composition can be usefully used as a composition for the treatment, prevention or improvement of human or animal intestinal damage.

Inventors

• Hwa Sup CHIN

Assignees

• LISCURE BIOSCIENCES CO., LTD.

Dates

Publication Date

20260505

Application Date

20220207

Priority Date

20210208

Claims (3)

1. 1 . A method for treating intestinal damage related to dysfunction of tight junction, the method comprising administering a composition comprising a Leuconostoc citreum WiKim0104 strain having accession number KCCM12420P and having the nucleic acid sequence of SEQ ID NO: 1 or a culture comprising the Leuconostoc citreum WiKim0104 strain as an active ingredient to a subject in need thereof, wherein the intestinal damage is caused by inflammatory bowel disease or chemotherapy.
2. 2 . The method of claim 1 , wherein the composition is administered via oral administration or parenteral administration.
3. 3 . The method of claim 2 , wherein the parenteral administration method is intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration or intrarectal administration.

Description

CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/KR2022/001870 filed Feb. 7, 2022, claiming priority based on Korean Patent Application No. 10-2021-0017813 filed Feb. 8, 2021 and Korean Patent Application No. 10-2022-0014825 filed Feb. 4, 2022, the entire disclosures of which are incorporated herein by reference. INCORPORATION BY REFERENCE OF SEQUENCE LISTING The content of the electronically submitted sequence listing, file name: Q289667_sequence listing as filed. TXT; size: 2,376 bytes; and date of creation: Aug. 7, 2023, filed herewith, is incorporated herein by reference in its entirety. TECHNICAL FIELD The present invention relates to a composition comprising a Leuconostoc citreum strain or a culture thereof as an active ingredient for preventing, improving or treating intestinal damage, specifically intestinal damage caused by inflammatory bowel disease, non-alcoholic steatohepatitis, and chemotherapy. BACKGROUND ART As the modern people have undesirable dietary habits and unhealthy lifestyles such as meat-oriented dietary life, instant and processed food-oriented eating habits, excessive intake of stimulating foods, and changes in food intake patterns that have become hasty due to a busy living environment, and get older, harmful bacteria are superior to beneficial bacteria, and the balance of intestinal bacteria is broken, which adversely affects the health of the intestine. The modern people are exposed to various intestinal diseases, and many people not only suffer from intestinal damage due to diseases such as inflammatory bowel disease, non-alcoholic steatohepatitis, and colorectal cancer, but also have problems in recovery of intestinal damage and maintenance of functions due to intestinal damage even after treatment. Microbiota refers to a microbial community in an environment as a microbial flora, and it is known that the microbiota plays an important role in maintaining homeostasis of a host, for example, human immunity, metabolites, and the like. The microbiota and the host exchange chemical signals, and the expression of immune cells, the production of neurotransmitters, short chain fatty acids (SCFA), and the like by the microbiota have a hypertrophic effect on a host system, and particularly, probiotics/prebiotics balance the unbalanced microbiota of the host, so that the metabolites of the healthy microbiota may improve the health of the host. Currently, there are published a composition for preventing or treating alcoholic intestinal damage containing probiotics as an active ingredient (Korean Patent Registration No. 10-2038695) and a composition for improving an intestinal environment containing a novel Lactobacillus acidophilus strain (Korea Patent Registration No. 10-2201517), but there is no description about a preventive or therapeutic effect of intestinal damage using a Leuconostoc citreum strain as an active ingredient. Under this background, the present inventors found that a composition containing a Leuconostoc citreum strain or a culture thereof, which had little toxicity and side effects, had an effect of treating intestinal damage and restoring functions on the intestine damaged by inflammatory bowel disease, non-alcoholic steatohepatitis, chemotherapy, etc., and then completed the present invention. DISCLOSURE Technical Problem An object of the present invention is to provide a pharmaceutical composition for preventing or treating intestinal damage comprising a Leuconostoc citreum strain as an active ingredient. Further, another object of the present invention is to provide a food composition or food additive composition for preventing or improving intestinal damage including a Leuconostoc citreum strain as an active ingredient. Further, yet another object of the present invention is to provide a feed composition or feed additive composition for preventing or improving livestock intestinal damage including a Leuconostoc citreum strain as an active ingredient. Technical Solution An aspect of the present invention provides a pharmaceutical composition for preventing or treating intestinal damage including a Leuconostoc citreum strain or its culture as an active ingredient. Further, another aspect of the present invention provides a food composition or food additive composition for preventing or improving intestinal damage including a Leuconostoc citreum strain or its culture as an active ingredient. Further, yet another aspect of the present invention provides a feed composition or feed additive composition for preventing or improving livestock intestinal damage including a Leuconostoc citreum strain or its culture as an active ingredient. Advantageous Effects An aspect of the present invention provides a pharmaceutical composition for preventing or treating intestinal damage including a Leuconostoc citreum strain or its culture as an active ingredient. Further, another aspect of the present invention provides